In vitro detection of cancer cells using a novel fluorescent choline derivative.

IF 2.9 3区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Anna E Caprifico, Luca Vaghi, Peter Spearman, Gianpiero Calabrese, Antonio Papagni
{"title":"In vitro detection of cancer cells using a novel fluorescent choline derivative.","authors":"Anna E Caprifico, Luca Vaghi, Peter Spearman, Gianpiero Calabrese, Antonio Papagni","doi":"10.1186/s12880-024-01488-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The treatment of preinvasive lesions is more effective than treating invasive disease, hence detecting cancer at its early stages is crucial. However, currently, available screening methods show various limitations in terms of sensitivity, specificity, and practicality, thus novel markers complementing traditional cyto/histopathological assessments are needed. Alteration in choline metabolism is a hallmark of many malignancies, including cervical and breast cancers. Choline radiotracers are widely used for imaging purposes, even though many risks are associated with their radioactivity. Therefore, this work aimed to synthesise and characterise a non-radioactive choline tracer based on a fluorinated acridine scaffold (CFA) for the in vitro detection of cervical and breast cancer cells by fluorescence imaging.</p><p><strong>Methods: </strong>CFA was fully characterised and tested for its cytotoxicity on breast (MCF-7), cervical (HeLa), glioblastoma (U-87 MG) and hepatoblastoma (HepG2) cancer cell lines and in normal cell lines (epithelial, HEK-293 and human dermal fibroblasts, HDFs). The cellular uptake of CFA was investigated by a confocal microscope and its accumulation was quantified over time. The specificity of CFA over mesenchymal origin cells (HDFs), as a model of cancer-associated fibroblasts was investigated by fluorescence microscopy.</p><p><strong>Results: </strong>CFA was toxic at much higher concentrations (HeLa IC<sub>50</sub> = 200 ± 18 µM and MCF-7 IC<sub>50</sub> = 105 ± 3 µM) than needed for its detection in cancer cells (5 µM). CFA was not toxic in the other cell lines tested. The intensity of CFA in breast and cervical cancer cells was not significantly different at any time point, yet it was greater than HepG2 and U-87 MG (p ≤ 0.01 and p ≤ 0.0001, respectively) after 24 h incubation. A very weak signal intensity was recorded in HEK-293 and HDFs (p ≤ 0.001 and p ≤ 0.0001, respectively). A selective ability of CFA to accumulate in HeLa and MCF-7 was recorded upon co-culture with fibroblasts.</p><p><strong>Conclusions: </strong>The results showed that CFA preferentially accumulated in cancer cells rather than in normal cells. These findings suggest that CFA may be a potential diagnostic probe for discriminating healthy tissues from malignant tissues due to its specific and highly sensitive features; CFA may also represent a useful tool for in vitro/ex vivo investigations of choline metabolism in patients with cervical and breast cancers.</p>","PeriodicalId":9020,"journal":{"name":"BMC Medical Imaging","volume":"24 1","pages":"316"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580358/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medical Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12880-024-01488-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The treatment of preinvasive lesions is more effective than treating invasive disease, hence detecting cancer at its early stages is crucial. However, currently, available screening methods show various limitations in terms of sensitivity, specificity, and practicality, thus novel markers complementing traditional cyto/histopathological assessments are needed. Alteration in choline metabolism is a hallmark of many malignancies, including cervical and breast cancers. Choline radiotracers are widely used for imaging purposes, even though many risks are associated with their radioactivity. Therefore, this work aimed to synthesise and characterise a non-radioactive choline tracer based on a fluorinated acridine scaffold (CFA) for the in vitro detection of cervical and breast cancer cells by fluorescence imaging.

Methods: CFA was fully characterised and tested for its cytotoxicity on breast (MCF-7), cervical (HeLa), glioblastoma (U-87 MG) and hepatoblastoma (HepG2) cancer cell lines and in normal cell lines (epithelial, HEK-293 and human dermal fibroblasts, HDFs). The cellular uptake of CFA was investigated by a confocal microscope and its accumulation was quantified over time. The specificity of CFA over mesenchymal origin cells (HDFs), as a model of cancer-associated fibroblasts was investigated by fluorescence microscopy.

Results: CFA was toxic at much higher concentrations (HeLa IC50 = 200 ± 18 µM and MCF-7 IC50 = 105 ± 3 µM) than needed for its detection in cancer cells (5 µM). CFA was not toxic in the other cell lines tested. The intensity of CFA in breast and cervical cancer cells was not significantly different at any time point, yet it was greater than HepG2 and U-87 MG (p ≤ 0.01 and p ≤ 0.0001, respectively) after 24 h incubation. A very weak signal intensity was recorded in HEK-293 and HDFs (p ≤ 0.001 and p ≤ 0.0001, respectively). A selective ability of CFA to accumulate in HeLa and MCF-7 was recorded upon co-culture with fibroblasts.

Conclusions: The results showed that CFA preferentially accumulated in cancer cells rather than in normal cells. These findings suggest that CFA may be a potential diagnostic probe for discriminating healthy tissues from malignant tissues due to its specific and highly sensitive features; CFA may also represent a useful tool for in vitro/ex vivo investigations of choline metabolism in patients with cervical and breast cancers.

使用新型荧光胆碱衍生物体外检测癌细胞。
导读治疗浸润前病变比治疗浸润性疾病更有效,因此在早期阶段检测癌症至关重要。然而,目前可用的筛查方法在灵敏度、特异性和实用性方面存在各种局限性,因此需要新的标记物来补充传统的细胞学/组织病理学评估。胆碱代谢的改变是包括宫颈癌和乳腺癌在内的许多恶性肿瘤的标志。胆碱放射性racers 被广泛用于成像目的,尽管其放射性存在许多风险。因此,这项研究旨在合成一种基于含氟吖啶支架(CFA)的非放射性胆碱示踪剂,并对其进行表征,以便通过荧光成像对宫颈癌和乳腺癌细胞进行体外检测:对 CFA 进行了全面鉴定,并测试了它对乳腺癌(MCF-7)、宫颈癌(HeLa)、胶质母细胞瘤(U-87 MG)和肝母细胞瘤(HepG2)细胞系以及正常细胞系(上皮细胞、HEK-293 和人真皮成纤维细胞,HDFs)的细胞毒性。共聚焦显微镜研究了细胞对 CFA 的摄取情况,并对其随时间的积累进行了量化。通过荧光显微镜研究了作为癌症相关成纤维细胞模型的间充质细胞(HDFs)对 CFA 的特异性:CFA的毒性浓度(HeLa IC50 = 200 ± 18 µM,MCF-7 IC50 = 105 ± 3 µM)远高于其在癌细胞中的检测浓度(5 µM)。在测试的其他细胞系中,CFA 没有毒性。乳腺癌和宫颈癌细胞中 CFA 的强度在任何时间点都没有显著差异,但在孵育 24 小时后,其强度高于 HepG2 和 U-87 MG(分别为 p ≤ 0.01 和 p ≤ 0.0001)。在 HEK-293 和 HDFs 中记录到的信号强度很弱(分别为 p≤0.001 和 p≤0.0001)。在与成纤维细胞共培养时,CFA在HeLa和MCF-7中具有选择性蓄积能力:结论:研究结果表明,CFA 优先在癌细胞而非正常细胞中积累。这些研究结果表明,由于 CFA 具有特异性和高灵敏度的特点,它可能是鉴别健康组织和恶性组织的潜在诊断探针;CFA 也可能是宫颈癌和乳腺癌患者体内/体外胆碱代谢研究的有用工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Medical Imaging
BMC Medical Imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
4.60
自引率
3.70%
发文量
198
审稿时长
27 weeks
期刊介绍: BMC Medical Imaging is an open access journal publishing original peer-reviewed research articles in the development, evaluation, and use of imaging techniques and image processing tools to diagnose and manage disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信